This company develops genomic technology focused on improving the safety and characterization of gene editing tools for cell and gene therapies. Their INDUCE-seq platform enables developers to accurately detect on- and off-target edits associated with gene editing systems like CRISPR. This technology supports the standardization and acceleration of safer gene-edited therapeutic development.
Funding
$16M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MRFounders
Product
Problem
CRISPR-Cas9 gene editing holds immense therapeutic potential, but off-target effects—unintended DNA edits at sites other than the intended target—pose a significant safety and efficacy challenge for cell and gene therapies. Accurately characterizing these off-target events is critical for ensuring the safety and precision of gene-editing based treatments.
Solution
Broken String Biosciences offers the INDUCE-seq® platform, a technology designed for comprehensive characterization of genome breaks, including on- and off-target effects, in cell and gene therapies. The platform enables direct measurement and quantification of DNA double-strand breaks (DSBs) in edited cells, revealing insights into factors affecting off-target activity. By mapping these breaks across the genome, INDUCE-seq enhances the development of safer and more effective gene-editing therapeutics. The platform's sensitivity allows for the identification of topology-related off-target events, which sequence analysis alone cannot predict.
Target Audience
The primary target audience includes cell and gene therapy developers, researchers, and clinical organizations focused on enhancing the safety and efficacy of CRISPR-based therapeutics.
Features
- Direct, in-cell measurement of on- and off-target CRISPR-Cas9 activity
- High-resolution DNA break mapping across the entire genome
- Identification of off-target events influenced by DNA topology and structural changes
- Validated in peer-reviewed research, demonstrating sensitivity and accuracy
- Compatible with various cell and gene therapy applications
- Catalyst Early Access Program for rapid on- and off-target edit detection